GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

GSK plc American Depositary Shares (Each representing two)

Citi analyst Graham Parry initiated coverage with a Hold rating on GlaxoSmithKline today and set a price target of £21.00. According to TipRanks, P...

Citi Initiates a Hold Rating on GlaxoSmithKline (GSK)

GlaxoSmithKline ( ($GSK) ) has issued an announcement. On July 22, 2026, GSK notified the market of a personal dealing transaction by Maya Martinez...

GSK Discloses July 22 Executive ADS Acquisition by U.S. President

An announcement from GlaxoSmithKline ( ($GSK) ) is now available. On 24 July 2026, GSK plc reported that 70,759 additional ordinary shares of 31¼ p...

GSK Adds 70,759 Shares to LSE Listing Under 2022 Share Save Plan

J.P. Morgan analyst Zain Ebrahim maintained a Sell rating on GlaxoSmithKline today and set a price target of £17.00. According to TipRanks, Ebrahim...

J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running a Phase 1 study called “A Phase 1, Open-Labe...

GSK’s New Malaria Candidate Advances With Key Drug-Interaction Study

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline has updated a key pediatric study on its IV flu drug za...

GSK Updates Key Pediatric Flu Study, Signaling Quiet Upside for Its Antiviral Portfolio

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The ALANIS study from GlaxoSmithKline (GSK) is a Phase 2 trial testing ...

GSK’s ALANIS Trial: Fresh Momentum in AL Amyloidosis Could Reshape Investor Views

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK tests vaccines for heart risk in adults 50+. The study, “A Randomiz...

GSK Explores Heart Health Upside From Its Next-Gen Vaccines

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK Bioavailability Trial Offers Fresh Insight for Asthma Investors. Th...

GSK’s New Asthma Injection Study: Early Signals for Long-Term Investors

Jefferies analyst Michael Leuchten maintained a Buy rating on GlaxoSmithKline today and set a price target of £25.00. According to TipRanks, Leucht...

GlaxoSmithKline (GSK) Gets a Buy from Jefferies

In a report released today, Zain Ebrahim from J.P. Morgan maintained a Sell rating on GlaxoSmithKline, with a price target of £17.00. According to ...

GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan

Shares in drugs giant GlaxoSmithKline ($GSK) were off-color today after it revealed that it was halting development of a chronic cough treatment af...

GSK Stock Weakens After Failed Drug Trial to Help Patients Coughing 900 Times a Day

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is launching a Phase 1 trial to test an infant pneumoco...

GSK Advances New Infant Pneumococcal Vaccine Into Early-Stage Testing

The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has disclosed a series of transactions in which several senior executives and non-...

GSK executives boost holdings via dividend-funded ADS purchases

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is launching a Phase 3 trial called BEHOLD-Endometrial0...

GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The BEHOLD-Ovarian02 Phase 3 study from GlaxoSmithKline (GSK) tests a n...

GSK’s BEHOLD-Ovarian02 Trial: A Fresh Late-Stage Bet in Ovarian Cancer

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is launching a phase 3 trial called BEHOLD-Ovaria...

GSK’s New Phase 3 Ovarian Cancer Trial Puts Mo-Rez in the First-Line Spotlight

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has completed its acquisition of Nuvalent, Inc., a clinical-stage oncology specialist, i...

GSK Pays $10.6 Billion for Nuvalent to Accelerate Lung Cancer Push

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK has disclosed a series of routine share transactions by several senior executives,...

GSK Executives Reinvest Dividends in Routine Share Purchases

J.P. Morgan Sticks to Their Sell Rating for GlaxoSmithKline (GSK)

Guggenheim analyst maintained a Hold rating on GlaxoSmithKline yesterday. The company’s shares closed today at p1,959.50. In addition to Guggenheim...

Guggenheim Remains a Hold on GlaxoSmithKline (GSK)

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK’s licensor Hansoh Pharma has reported that the pivotal ARTEMIS-008 phase III trial...

GSK’s Partner Delivers Landmark Lung Cancer Data for B7-H3 ADC

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The study, officially titled “A Phase 3, Non-randomized, Single-arm, Op...

GSK Boosts Vaccine Pipeline With New Adolescent dTpa Trial in Japan

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK steps up its respiratory vaccine push with a new study, NCT07628049...

GSK’s New RSV/hMPV Vaccine Trial Adds Momentum to Its Respiratory Portfolio

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK Advances Maternal Vaccine Program in Japan. The new Phase 3 study l...

GSK Steps Up Maternal Vaccine Push With New Phase 3 Study in Japan

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running a Phase 3 study called “A Phase 3a, Observer...

GSK Targets Pediatric Vaccine Growth With New Phase 3 Trial Against Merck’s ProQuad

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is launching a Phase 2A study called “A Phase 2A Study ...

GSK Advances Novel Malaria Drug Into Phase 2A, Signaling Long-Term Global Health Upside

Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £19.00. According to TipRanks, Gordon...

Barclays Remains a Sell on GlaxoSmithKline (GSK)

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is launching a Phase 3 study called StrateGIST Frontlin...

GSK’s StrateGIST Frontline Trial Puts New Cancer Drug Velzatinib in the Spotlight

GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK has reported that, as of 30 June 2026, its issued share capital comprises 4,316,276,428 o...

GSK Updates Market on Total Voting Rights as of 30 June 2026

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK Tests Dual mRNA Vaccine for Flu and COVID-19 in Older Adults. The s...

GSK’s New mRNA Combo Shot Targets Flu and COVID-19 in One Vaccine

HSBC Holdings ($HSBC) has been one of the best-performing big bank stocks in the world over the past year — up approximately 66% on a total return ...

You Bought HSBC for the Bank. Not the British Pound. Here’s the ETF That Keeps It That Way.

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has completed a share buyback programme of up to £2 billion, executed thro...

GSK Completes £2 Billion Share Buyback, Lifts Treasury Holdings to 6.7% of Voting Rights

J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)

Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £19.00. Gordon CFA covers the Healthc...

GlaxoSmithKline (GSK) Gets a Sell from Barclays

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The Extended Salford Lung Study (Ex-SLS) Data Access Project from GSK t...

GSK’s Extended Salford Lung Study: What a Terminated Data Project Still Means for Investors

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running the BALANCE Phase 2b study to test camlipixa...

GSK Advances BALANCE Trial: New IBS Drug Candidate Moves Through Mid‑Stage Testing

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running the Phase 3b/4 MODIFY study to test early us...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GSK	$51.35	+1.20%	5.86M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GSK	$51.35	+1.2%	5.86M
3
4
5
6

GSK

GSK

Get GSK plc American Depositary Shares (Each representing two) Data in Excel

Get GSK plc American Depositary Shares (Each representing two) Data in Excel